Tissue Diagnostics Market Research Report by Regional Analysis - North America, Europe, Asia Pacific, Latin America, Middle East & Africa : forecast 2024

Tissue diagnostics is a technique used for diagnosis, monitoring, and management of diseases. It is one of the major techniques used in cancer diagnosis. Currently, there are various types of cancer including breast, colon, lung, prostate, liver, skin, stomach, and others. Globally, cancer is one the leading cause of death. According to the WHO, cancer accounted for 8.2 million deaths in 2012. According to the American Cancer Society, one million people are diagnosed with cancer every year. Tissue diagnostics plays an important role in diagnosis and detection of cancer. Tissue diagnostics is also useful in next generation sequencing, decoding cancer molecular profiles, and circulating cancer cells. Tissue diagnostics is experiencing significant growth due to increasing incidence of cancer, microbial infections, autoimmune diseases, and various other diseases. Tissue-based diagnostic testing comprises histopathology, which is the study of disease in tissue, and various other diagnostic tests such as immunohistochemistry, in situ hybridization, hematoxylin, and Eosin test. Tissue diagnostic test is performed using a fine needle aspiration cytology, open biopsy, and core biopsy. Tissue diagnostics also helps to detect the degree of healthy tissue been affected by cancer and the stage of cancer. Tissue diagnosis in biopsy helps to determine the course of treatment.

The tissue diagnostics market is driven by increasing prevalence of cancer, technical advances in tissue diagnostic tests, increasing usage of immunohistochemistry products, research and development and increasing investment in diagnostic procedures of small tissues, and increasing investment by pharmaceutical companies. High cost of the test, stringent regulatory framework for approval of medical devices, and no proper reimbursement policy are the major restraints of the market. However, innovation in the diagnostic tests such as IHC, ISH, and FISH is likely to provide an opportunity in the global tissue diagnostic market.

Browse full report on Tissue Diagnostics Market -
http://www.transparencymarketresearch.com/tissue-diagnostics-market.html

The tissue diagnostics market has been segmented based on technology, application, end-user, and region. In terms of technology, the market has been categorized into flow cytometry, HPV test, hematology, in situ hybridization, immunohistochemistry, circulating tumor cells, pap smears, microscopy, and digital or image cytometry. Based on application, the tissue diagnostics market has been segmented into hematology, oncology, microbiology, tissue transplant, prenatal testing, and cytology. In terms of end-user, the tissue diagnostics market has been segmented into pharmaceutical companies, contract research organizations, research laboratories, hospitals, and diagnostic centers.

In terms of region, the tissue diagnostics market was segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the tissue diagnostics market due to increasing awareness regarding new diagnostic tests available, growing emphasis on early detection of cancer, improved reimbursement policy, and well developed health care facilities. The legislative reform of Affordable Care Act in the U.S. is also an important factor likely to drive the tissue diagnostics market in North America. Europe is the second largest market for tissue diagnostics due to improved health care facilities and economic condition. Moreover, medical innovation and increasing awareness are factors attributed to the growth of the tissue diagnostics market. Asia Pacific is expected to be the emerging market for tissue diagnostics, with India and China being major markets. Latin America and Middle East & Africa are expected to be other key markets for tissue diagnostics.

Top players in the tissue diagnostics market are F. Hoffmann-La Roche AG., Sigma-Aldrich Corporation, Abbott, BioGenex Laboratories, BioSB, Cell Signaling Technology, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, GE Healthcare, and Siemens Healthineers, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19607

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.